Business
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference
SAN JOSE, Calif., Sept. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, Calif., Sept. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. (\"Anixa\" or the \"Company\") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer Research Alliance's (\"OCRA\") International Gynecologic Cancer Conference taking place online September 25-27, 2024. \n\n \n \n \n \n \n \n\n \nThe presentation, entitled \"Autologous T Cells Engineered to Target Follicle Stimulating Hormone (FSH) Receptor in Recurrent Ovarian Cancer, A Phase 1 Trial,\" will be presented by Dr. Pamela Garzone, Anixa's Chief Development Officer, and will discuss the clinical development of Anixa's novel chimeric antigen receptor T cell (CAR-T) therapy for ovarian cancer. The presentation will take place at 3:00PM ET on September 25.\nThe International Gynecologic Cancer Conference is organized by OCRA. OCRA is the leading organization in the world fighting ovarian cancer from all fronts while supporting women and their families.\nMore information about the event may be found at: International Gynecologic Cancer Conference - Ovarian Cancer Research Alliance (ocrahope.org).\nAbout Anixa's CAR-T Approach (Follicle Stimulating Hormone Receptor-Mediated CAR-T technology)Anixa's chimeric antigen receptor-T cell (CAR-T) technology approach is an autologous cell therapy comprised of engineered T cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone (chimeric endocrine) receptor, and the target-binding domain is derived from its natural ligand, this technology is known as CER-T (chimeric endocrine receptor-T cell) therapy, a new type of CAR-T. Anixa's FSHR-mediated CAR-T technology was developed by Jose R. Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine. Anixa holds an exclusive world-wide license to the technology from The Wistar Institute.\nAbout Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a ...